	US 12,280,141 B2
	Liquid depot for non-invasive sustained delivery of agents to the eye
Vernon G. Wong, Menlo Park, CA (US); and Glenn T. Huang, Fremont, CA (US)
Assigned to Chibi, Inc., Menlo Park, CA (US)
Filed by CHIBI, INC., Menlo Park, CA (US)
Filed on Dec. 9, 2021, as Appl. No. 17/547,028.
Application 17/547,028 is a continuation of application No. 16/909,242, filed on Jun. 23, 2020, granted, now 11,234,926.
Application 16/909,242 is a continuation of application No. PCT/US2019/030294, filed on May 1, 2019.
Claims priority of provisional application 62/665,367, filed on May 1, 2018.
Prior Publication US 2022/0168219 A1, Jun. 2, 2022
Int. Cl. A61K 31/5575 (2006.01); A61K 9/00 (2006.01); A61K 31/355 (2006.01); A61K 31/4709 (2006.01); A61K 31/573 (2006.01); A61K 31/575 (2006.01); A61K 47/14 (2017.01); A61K 47/22 (2006.01); A61P 27/02 (2006.01); A61P 27/06 (2006.01)

CPC A61K 9/0048 (2013.01) [A61K 31/4709 (2013.01); A61K 31/573 (2013.01); A61K 31/575 (2013.01); A61K 47/14 (2013.01); A61K 47/22 (2013.01)]

7 Claims

1. A method of treating glaucoma in a subject in need thereof, comprising topically administering to an eye of the subject with an eyedropper, a liquid depot consisting of latanoprost from 0.03% to 0.05%; tocopheryl acetate from 80% to 85% (wt %) and medium-chain triglycerides from 15%-20% (wt %); and wherein the liquid depot has a viscosity of no more than 1100 cP.